
Seven patients with hyperthyroidism due to a TSH-secreting pituitary macroadenoma have been observed of a total of 800 patients with pituitary tumors over a period of 15 yr. Serum TSH levels varied between 1.1-36.3 mU/L. The serum alpha-subunit level was low in 1 case, while in 4 other cases the concentration was elevated and varied between 3.7-7.8 micrograms/L. Serum TSH beta levels were normal in the 4 cases in which it was determined. Serum GH or PRL levels were elevated in 5 cases. In 1 patient the cosecretion of TSH, GH, and PRL was confirmed by immunocytochemical examination. Serum TSH and alpha-subunit responses to TRH, GnRH, CRF, GRF, dexamethasone, methimazole, T3, and bromocriptine administration were variable when studied. Serum TSH and alpha-subunit circadian rhythms were absent in 1 case and inverted in another. A serum alpha-subunit pulsatility without TSH pulses was observed in 1 patient. Five patients underwent transsphenoidal adenomectomy. Three of 4 patients operated on in our center were cured, but a recurrence of the adenoma was found in 1 of them after 5 yr. The fifth patient was not cured. Treatment with octreotide in 3 patients resulted in normalization of serum TSH, GH, and thyroid hormones levels. Cosecretion of PRL in 1 case and alpha-subunit in 2 cases was also inhibited. Partial tachyphylaxis occurred in 1 patient. In summary, heterogeneity in clinical presentation, hormonal expression, and therapeutic response appears to characterize these TSH-secreting adenomas.
Adenoma, Adult, Male, Adolescent, Hyperthyroidism/drug therapy/etiology, Thyrotropin/blood/secretion, Thyrotropin, Octreotide, Sciences de la santé humaine, Hyperthyroidism, Endocrinology, metabolism & nutrition, Thyrotropin-Releasing Hormone/diagnostic use, Humans, Pituitary Neoplasms, Human health sciences, Adenoma/complications/secretion/therapy, Thyrotropin-Releasing Hormone, Bromocriptine, Aged, Methimazole/diagnostic use/therapeutic use, Aged, 80 and over, Methimazole, Bromocriptine/diagnostic use, Pituitary Neoplasms/complications/secretion/therapy, Growth Hormone/blood, Octreotide/therapeutic use, Middle Aged, Glycoprotein Hormones, alpha Subunit/blood, Circadian Rhythm, Prolactin, Prolactin/blood, Glycoprotein Hormones, alpha Subunit, Growth Hormone, Female, Endocrinologie, métabolisme & nutrition
Adenoma, Adult, Male, Adolescent, Hyperthyroidism/drug therapy/etiology, Thyrotropin/blood/secretion, Thyrotropin, Octreotide, Sciences de la santé humaine, Hyperthyroidism, Endocrinology, metabolism & nutrition, Thyrotropin-Releasing Hormone/diagnostic use, Humans, Pituitary Neoplasms, Human health sciences, Adenoma/complications/secretion/therapy, Thyrotropin-Releasing Hormone, Bromocriptine, Aged, Methimazole/diagnostic use/therapeutic use, Aged, 80 and over, Methimazole, Bromocriptine/diagnostic use, Pituitary Neoplasms/complications/secretion/therapy, Growth Hormone/blood, Octreotide/therapeutic use, Middle Aged, Glycoprotein Hormones, alpha Subunit/blood, Circadian Rhythm, Prolactin, Prolactin/blood, Glycoprotein Hormones, alpha Subunit, Growth Hormone, Female, Endocrinologie, métabolisme & nutrition
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 109 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
